Charles Schwab
KURA icon

Charles Schwab’s Kura Oncology KURA Stock Holding History

Charles Schwab’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42M Sell
676,400
-14,417
-2% -$136K ﹤0.01% 2294
2026
Q1 		$5.62M Sell
690,817
-20,065
-3% -$172K ﹤0.01% 2357
2025
Q4 		$7.39M Sell
710,882
-1,014
-0.1% -$10.6K ﹤0.01% 2281
2025
Q3 		$6.3M Buy
711,896
+12,593
+2% +$89.8K ﹤0.01% 2326
2025
Q2 		$4.03M Buy
699,303
+76,163
+12% +$467K ﹤0.01% 2417
2025
Q1 		$4.11M Sell
623,140
-12,354
-2% -$96.3K ﹤0.01% 2352
2024
Q4 		$5.54M Buy
635,494
+10,542
+2% +$152K ﹤0.01% 2293
2024
Q3 		$12.2M Buy
624,952
+14,106
+2% +$286K ﹤0.01% 1938
2024
Q2 		$12.6M Buy
610,846
+12,122
+2% +$249K ﹤0.01% 1923
2024
Q1 		$12.8M Buy
598,724
+18,737
+3% +$364K ﹤0.01% 1863
2023
Q4 		$8.34M Buy
579,987
+16,566
+3% +$163K ﹤0.01% 2081
2023
Q3 		$5.14M Buy
563,421
+86,141
+18% +$875K ﹤0.01% 2243
2023
Q2 		$5.05M Buy
477,280
+6,289
+1% +$74.4K ﹤0.01% 2236
2023
Q1 		$5.76M Buy
470,991
+1,959
+0.4% +$24.4K ﹤0.01% 2135
2022
Q4 		$5.82M Buy
469,032
+17,679
+4% +$257K ﹤0.01% 2140
2022
Q3 		$6.17M Sell
451,353
-18,236
-4% -$281K ﹤0.01% 2108
2022
Q2 		$8.61M Sell
469,589
-8,328
-2% -$120K ﹤0.01% 1919
2022
Q1 		$7.68M Buy
477,917
+12,237
+3% +$177K ﹤0.01% 2080
2021
Q4 		$6.52M Buy
465,680
+11,190
+2% +$181K ﹤0.01% 2220
2021
Q3 		$8.51M Buy
454,490
+3,819
+0.8% +$72K ﹤0.01% 2097
2021
Q2 		$9.4M Buy
450,671
+7,444
+2% +$185K ﹤0.01% 2036
2021
Q1 		$12.5M Buy
443,227
+21,588
+5% +$683K ﹤0.01% 1827
2020
Q4 		$13.8M Buy
421,639
+61,621
+17% +$2.17M 0.01% 1663
2020
Q3 		$11M Buy
360,018
+30,689
+9% +$678K 0.01% 1630
2020
Q2 		$5.37M Buy
329,329
+76,668
+30% +$1.11M ﹤0.01% 1993
2020
Q1 		$2.51M Buy
252,661
+1,993
+0.8% +$22.8K ﹤0.01% 2179
2019
Q4 		$3.45M Buy
250,668
+6,640
+3% +$98.4K ﹤0.01% 2214
2019
Q3 		$3.7M Buy
244,028
+13,617
+6% +$242K ﹤0.01% 2132
2019
Q2 		$4.54M Buy
230,411
+6,380
+3% +$106K ﹤0.01% 2015
2019
Q1 		$3.72M Buy
224,031
+61,451
+38% +$947K ﹤0.01% 2124
2018
Q4 		$2.28M Sell
162,580
-2,144
-1% -$28.4K ﹤0.01% 2284
2018
Q3 		$2.88M Buy
164,724
+107,589
+188% +$2.06M ﹤0.01% 2300
2018
Q2 		$1.04M Buy
57,135
+11,961
+26% +$203K ﹤0.01% 2574
2018
Q1 		$848K Buy
45,174
+4,200
+10% +$81.8K ﹤0.01% 2569
2017
Q4 		$627K Buy
40,974
+1,774
+5% +$26.1K ﹤0.01% 2669
2017
Q3 		$587K Buy
39,200
+14,900
+61% +$140K ﹤0.01% 2670
2017
Q2 		$226K Buy
+24,300
New +$221K ﹤0.01% 2987

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Charles Schwab's KURA Position: Q2 2026 in Review

Charles Schwab reduced its Kura Oncology (KURA) stake by 2.1% in Q2 2026, selling an estimated $136K and leaving 676,400 shares worth $7.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Charles Schwab first reported a position in KURA in Q2 2017 and has held it in 37 quarters since. The position peaked at $13.8M in Q4 2020. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Charles Schwab held 676,400 shares of Kura Oncology worth $7.42M as of Q2 2026.
  • Charles Schwab sold 14,417 Kura Oncology shares in Q2 2026, an estimated $136K.
  • Kura Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2294 holding.
  • Charles Schwab first reported a position in Kura Oncology in Q2 2017 and has held it in 37 quarters since.
  • Charles Schwab's Kura Oncology position peaked at $13.8M in Q4 2020.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.